(Q33973980)

30 July 2017

title

Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment (English)

1 reference

30 July 2017

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

3 April 2024

3

M. M. Khan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623492

3 April 2024

author name string

D. R. Evans

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623492

3 April 2024

V. V. Parikh

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623492

3 April 2024

C. Coussons

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623492

3 April 2024

P. F. Buckley

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623492

3 April 2024

S. P. Mahadik

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623492

3 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14623492

3 April 2024

publication date

1 December 2003

1 reference

full work available at URL

30 July 2017

https://api.elsevier.com/content/article/PII:S0952327803001625?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

https://api.elsevier.com/content/article/PII:S0952327803001625?httpAccept=text/plain

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Prostaglandins, Leukotrienes and Essential Fatty Acids

3 April 2024

published in

1 reference

30 July 2017

volume

69

1 reference

30 July 2017

issue

6

1 reference

30 July 2017

page(s)

393-399

1 reference

The membrane hypothesis of schizophrenia

30 July 2017

cites work

3

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition

3 April 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures

3 April 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis

3 April 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects.

3 April 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics

3 April 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia

3 April 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases

3 April 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation

3 April 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

3 April 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia

3 April 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Free radical pathology and antioxidant defense in schizophrenia: a review

3 April 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Free radical pathology in schizophrenia: a review

3 April 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2.

3 April 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls.

3 April 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

The positive and negative syndrome scale (PANSS) for schizophrenia

3 April 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Impaired antioxidant defense at the onset of psychosis.

3 April 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Elevated plasma lipid peroxides at the onset of nonaffective psychosis

3 April 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group

3 April 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain

3 April 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Fat consumption and schizophrenia.

3 April 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Smoking habits and plasma lipid peroxide and vitamin E levels in never-treated first-episode patients with schizophrenia

3 April 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications

3 April 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Antioxidants in the treatment of schizophrenia

3 April 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia

3 April 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.010

3 April 2024

Identifiers

1 reference

30 July 2017

1 reference